Elevated serum calprotectin as an inflammatory marker in obstructive sleep apnea

Kum, Nurcan Yurtsever; Kum, Rauf Oğuzhan; Çandar, Tuba; Baklacı, Deniz; Güler, İsmail; Kuzucu, İhsan; Özcan, Kürşat Murat; Özcan, Müge; Dere, Hüseyin

doi:10.1080/08869634.2020.1839721

Cited by 5 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Calprotectin level is elevated in patients with moderate and severe obstructive sleep apnea [ 53 ]). Similarly, Torun’s study showed that it could be used as a marker for the severity of obstructive sleep apnea syndrome [ 54 , 55 ].…”

Section: Discussionmentioning

confidence: 99%

Calprotectin, Biomarker of Depression in Patients with Inflammatory Bowel Disease?

et al. 2023

View full text Add to dashboard Cite

Background and Objectives: Calprotectin is a marker for intestinal inflammation. Recent research suggests a link between inflammation and depression. This study assessed the association between the levels of calprotectin in patients from South-Eastern Europe and the severity of depression, anxiety, and quality of life. Materials and Methods: This cross-sectional study included 30 confirmed patients with Crohn’s disease (CD) and ulcerative colitis (UC) who were assessed using clinical interviews for determining the severities of mental disorders (i.e., depression severity—PHQ-9, anxiety—GAD-7) and the quality of life (EQ-5D). Stool samples were collected from all participants for measuring their levels of calprotectin. Results: The level of calprotectin is correlated with PHQ-9 (ρ = 0.416, p = 0.022) and EQ-5D (ρ = −0.304, p = 0.033) but not with GAD 7 (ρ = 0.059, p = 0.379). Calprotectin levels in patients with mild, moderate, and moderately severe depression were significantly higher than in patients with minimal depression (198 µg/g vs. 66,9 µg/g, p = 0.04). Calprotectin level was corelated with the following depressive symptoms: autolytic ideation (ρ = 0.557, p = 0.001), fatigue (ρ = 0.514, p = 0.002), slow movement (ρ = 0.490, p = 0.003), and sleep disorders (ρ = 0.403, p = 0.014). Calprotectin was an independent predictor of depression with an odds ratio of 1.01 (95%: 1.002–1.03, p < 0.01). An ROC analysis showed that a level of calprotectin of 131 µg/g or higher has a sensitivity of 82%, a specificity of 61%, and an accuracy of 70% for predicting depression. In this study, no significant correlations were found between calprotectin level and anxiety. Conclusions: Calprotectin levels are associated with the severity of depression, and checking for a calprotectin level of 131 µg/g or higher may be a potential accessible screening test for depression in patients with inflammatory bowel disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Calprotectin, Biomarker of Depression in Patients with Inflammatory Bowel Disease?

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Recently, it was shown that Calprotectin is a biomarker of inflammation that can be used to track the progression of numerous inflammatory diseases. [23][24][25][26][27][28] Limited research studies look at the connection between the severity and predicator value of serum Calprotectin in COVID-19. Patients brought to the ICU had significantly higher serum levels of Calprotectin than non-ICU patients, and those who died had much higher levels, according to Chen et al, 18 who conducted a study with 121 COVID-19 patients (41 ICU, 81 non-ICU).…”

Section: Discussionmentioning

confidence: 99%

Physiological effects of Calprotectin and B Cell activating factor in COVID-19 Patients

Balaky

Mustafa

Ismail

et al. 2023

J. Contemp. Med. Sci.

View full text Add to dashboard Cite

Objectives: This study set out to determine how Calprotectin and B cell activating factor contributes to early COVID-19 patient severity prediction. Methods: The study included 25 healthy controls and 52 patients with SARS-COV2 infection who were clinically diagnosed with COVID-19 illness and were between the ages of 23 and 35. The serum levels of CALP and BAFF were measured using the ELISA method. To gauge CRP levels, an immunoturbidometric assay was performed. Results: Variations in serum levels of CALP and BAFF were found to be statistically insignificant in the study (P=0.7109 & P=0.7575, respectively). When compared to the control group (103.95±36.67 ng/mL; 403.03±1.03), COVID-19 patients had non-significantly raised levels of CALP and BAFF (106.5±4.67 ng/mL; 436.9±12.77 pg/mL, respectively). According to ROC curve analysis, the area under the receiver operating characteristics curve (AUC) for CALP and BAFF was (0.5170) and (0.5259), respectively. (r=0.6923; P=0.0001). There was a significant positive correlation between serum CALP and BAFF levels. The connection between serum CRP levels and CALP (r=0.3010; P=0.1271) and BAFF levels (r=0.2912; P=0.1406) was insignificantly positive. Conclusion: The current study's findings suggested that serum CALP and BAFF concentrations were increased in COVID-19 patients, suggesting that these inflammatory markers may be helpful indicators of the severity of COVID-19.

show abstract

Serum calprotectin as a novel biomarker for severity of COVID-19 disease

et al. 2021

View full text Add to dashboard Cite

Background Some biomarkers have been reported to be related to the prognosis of the coronavirus disease 2019 (COVID-19). There are sparse data regarding the prognostic value of serum calprotectin in COVID-19 patients. Aims This study aimed to investigate the relationship between serum calprotectin level and clinical severity of COVID-19 disease in hospitalized patients. Methods This retrospective cross-sectional cohort study included 80 consecutive hospitalized patients with confirmed diagnosis of COVID-19. The study population was divided into two groups as patients hospitalized in the intensive care unit (ICU) and patients hospitalized but not in the ICU. The serum calprotectin levels, other laboratory, and clinical parameters were compared between groups. Results The mean age of the patients was 66.5 ± 15.7 years. Of the patients, 42 were in the ICU and 38 were not. Serum calprotectin level and acute-phase reactants such as C-reactive protein, procalcitonin, ferritin, fibrinogen, and white blood cell were significantly higher in ICU patients than in non-ICU patients. ROC curve analysis identified that serum calprotectin level was a predictor for ICU requirement with an area under the curve of 0.641 ( p = 0.031). Logistic regression analysis revealed that serum calprotectin was a significant determinant for whether or not patient required the ICU. Conclusions These findings demonstrate that serum calprotectin level seems to be a useful biomarker that can predict the severity of COVID-19 disease. Serum calprotectin is a significant predictor of ICU requirement in patients with COVID-19.

show abstract

Elevated serum calprotectin as an inflammatory marker in obstructive sleep apnea

Cited by 5 publications

References 26 publications

Calprotectin, Biomarker of Depression in Patients with Inflammatory Bowel Disease?

Calprotectin, Biomarker of Depression in Patients with Inflammatory Bowel Disease?

Physiological effects of Calprotectin and B Cell activating factor in COVID-19 Patients

Serum calprotectin as a novel biomarker for severity of COVID-19 disease

Contact Info

Product

Resources

About